The Partners Genetics Collaborative Study of Schizophrenia

This study is ongoing, but not recruiting participants.

Sponsor:

Collaborator:

National Institute of Mental Health (NIMH)

Information provided by (Responsible Party):

Daphne Holt, Massachusetts General Hospital

ClinicalTrials.gov Identifier:

NCT00319904

First received: April 27, 2006

Last updated: March 16, 2016

Last verified: March 2016

History of Changes

Purpose

We will collect DNA from 500 rigorously diagnosed patients with schizophrenia to allow us in the future to examine phenotypic subtypes in relation to genetic variants. Phenotypes will include subgroups based on clinical symptoms, medication response, or other biological markers including neuroimaging or pharmacologic challenges.

Condition
Schizophrenia


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	The Partners Genetics Collaborative Study of Schizophrenia

Resource links provided by NLM:

Genetics Home Reference related topics: schizophrenia

MedlinePlus related topics: Schizophrenia

U.S. FDA Resources

Further study details as provided by Daphne Holt, Massachusetts General Hospital:

Primary Outcome Measures:

phenotypic subtypes in relation to genetic variants [ Time Frame: Baseline ]
We will collect DNA from 500 patients with schizophrenia to examine phenotypic subtypes in relation to genetic variants. Phenotypes will include subgroups based on clinical symptoms, medication response, or other biological markers including neuroimaging or pharmacologic challenges.

Biospecimen Retention: Samples With DNA

DNA is extracted and stored for future anaysis of genes that may be associated with schizophrenia


Estimated Enrollment:	500
Study Start Date:	March 2001
Estimated Study Completion Date:	October 2016
Estimated Primary Completion Date:	October 2016 (Final data collection date for primary outcome measure)

Show Detailed Description

Eligibility


Ages Eligible for Study:	18 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Adults with Schizophrenia

Criteria

Inclusion Criteria:

Schizophrenia, any subtype Ages 18-70 years Males or females English speaking Ability to complete symptom rating scales and cognitive tests Ability to provide informed consent

Exclusion Criteria:

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00319904

Locations


United States, Massachusetts
Freedom Trail Clinic
Boston, Massachusetts, United States, 02114

Sponsors and Collaborators

Massachusetts General Hospital

National Institute of Mental Health (NIMH)

Investigators


Principal Investigator:	Daphne J Holt, M.D., PhD	Massachusetts General Hospital

More Information

Publications:

Roffman JL, Gollub RL, Calhoun VD, Wassink TH, Weiss AP, Ho BC, White T, Clark VP, Fries J, Andreasen NC, Goff DC, Manoach DS. MTHFR 677C --> T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val --> Met. Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17573-8. doi: 10.1073/pnas.0803727105. Epub 2008 Nov 6.


Responsible Party:	Daphne Holt, Associate Professor of Psychiatry, Massachusetts General Hospital
ClinicalTrials.gov Identifier:	NCT00319904 History of Changes
Other Study ID Numbers:	2001-P-000560
Study First Received:	April 27, 2006
Last Updated:	March 16, 2016

Keywords provided by Daphne Holt, Massachusetts General Hospital:


Schizophrenia DNA

Additional relevant MeSH terms:


Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders

ClinicalTrials.gov processed this record on July 28, 2017

To Top